Synlogic (NASDAQ:SYBX – Get Free Report) will likely be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($5.80) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.
Synlogic Stock Performance
NASDAQ:SYBX opened at $1.00 on Wednesday. Synlogic has a 12-month low of $0.54 and a 12-month high of $1.86. The firm has a market cap of $12.25 million, a price-to-earnings ratio of -3.85 and a beta of 0.61. The company’s 50-day moving average is $1.12 and its two-hundred day moving average is $0.83.
About Synlogic
Synlogic, Inc was a clinical-stage biopharmaceutical company focused on developing medicines based on synthetic biology. Its platform used genetically engineered probiotic bacteria, known as Synthetic Biotics, designed to carry out specific therapeutic functions inside the gastrointestinal tract.
The company’s research programs targeted metabolic and gastrointestinal disorders. Its leading candidates included SYNB1934, an investigational treatment intended to help break down phenylalanine in people with phenylketonuria, and SYNB8802, which was designed to consume oxalate in the gut for the potential treatment of enteric hyperoxaluria.
Recommended Stories
- Five stocks we like better than Synlogic
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
